Alice Bhasale

Alice Bhasale

Auto-generated profile, based on publicly available information

Alice Bhasale

GAustralian Commission on Safety and Quality in Health Care, Sydney, NSW 2000, Australia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2020 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
ABAlice L. Bhasale
Alice L. Bhasale
ASAmeet Sarpatwari
Ameet Sarpatwari
MBMarie L De Bruin
Marie L De Bruin
JLJoel Lexchin
Joel Lexchin
RLRuth Lopert
Ruth Lopert
BMBarbara Mintzes
Barbara Mintzes

1 August 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ABAlice L. Bhasale
Alice L. Bhasale
ASAmeet Sarpatwari
Ameet Sarpatwari
WLWendy Lipworth
Wendy Lipworth
MMMathias Møllebæk
Mathias Møllebæk
EMEliza J. McEwin
Eliza J. McEwin
BMBarbara Mintzes
Barbara Mintzes


29 April 2020 in BMJ
Verified
Journal Article
Closed access
PDF file
ABAlice Bhasale
Alice Bhasale
BMBarbara Mintzes
Barbara Mintzes
ASAmeet Sarpatwari
Ameet Sarpatwari
As new risks of SGLT2 inhibitors have emerged, how have regulators responded? Alice Bhasale and colleagues compare the number, timing, strength, and transparency of public safety communications across leading medicines regulators

9 November 2020 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
AHAshleigh Hooimeyer
Ashleigh Hooimeyer
ABAlice Bhasale
Alice Bhasale
LPLucy Perry
Lucy Perry
AFAlice Fabbri
Alice Fabbri
AMAnnim Mohammad
Annim Mohammad
BMBarbara Mintzes
Barbara Mintzes
Information on rare adverse effects is often limited when a medication is initially approved for marketing. Medicines regulators use safety advisories to warn health professionals and consumers about emerging harms. This study aimed to identify characteristics and advice provided in cardiac safety advisories released by regulators in Australia, Canada, the United Kingdom, and the United States. This was a retrospective study of safety advisories about cardiac‐related adverse events issued by these four international medicines regulators between 2010 and 2016. A descriptive overview was followed by a more detailed content analysis, focusing on recommended actions for health professionals, including monitoring advice. For the latter, we applied the systematic information for monitoring (SIM) scale to assess adequacy. Over this period, 164 safety advisories about cardiac harms were issued by the four regulators. There were 61 drugs with advisories of cardiac risk, only 9 (14.7%) of which had advisories from all regulators in countries where the drug was approved. The most common adverse events were cardiac arrhythmias (n = 97, 59.1%) and coronary artery disorders (n = 39, 23.8%). The most frequent advice to prescribers was to monitor patients (n = 74, 45.1%), although only 41.2% of these advisories provided detailed advice on how monitoring should occur. We found many differences in the decision to warn and the advice provided. Patient monitoring was most often recommended, but key information such as frequency or thresholds for action was often lacking. Healthcare professionals and consumers need consistent information about rare serious harms so that they can make informed decisions.

3 October 2022 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
BMBarbara Mintzes
Barbara Mintzes
EREllen Reynolds
Ellen Reynolds
PBPriya Bahri
Priya Bahri
LPLucy T Perry
Lucy T Perry
ABAlice L Bhasale
Alice L Bhasale
CDColin R Dormuth
Colin R Dormuth
Many adverse effects of medicines only become known after approval, prompting regulatory agencies to issue post-market safety advisories to support safer care. Our team evaluated advisories issued ...